Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

2018/01/10 by Michael A. Postow, Robert Sidlow, Matthew D. Hellmann · 30 citations
Medicine · Immunology and Microbiology · #Cancer Immunotherapy and Biomarkers #Immune Cell Function and Interaction #Colorectal Cancer Treatments and Studies

paper · doi:10.1056/nejmra1703481

Abstract

The wide range of immune-related adverse effects associated with immune checkpoint blockade can complicate this effective therapy and limit its use in patients with cancer. This review surveys the adverse effects and their management.

Citations

• Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
• Commensal <i>Bifidobacterium</i> promotes antitumor immunity and facilitates anti–PD-L1 efficacy
• Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Cited by

• Adverse drug reactions associated with immune checkpoint inhibitors: An exploratory nested case-control study in a historical cohort
• Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma
• Immune checkpoint inhibitor-related neurotoxicity: Incidence and management. A systematic review and meta-analysis
• Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms
• Pembrolizumab‐caused polyradiculoneuropathy as an immune‐related adverse event
• 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
• Polymer-based hydrogels with local drug release for cancer immunotherapy
• IL-6 receptor blockade impedes proinflammatory atypical Treg subset associated with immune checkpoint inhibitor–induced inflammatory arthritis
• The Future of Personalized Cancer Vaccines
• Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy
• Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue
• Checkpoint inhibitors create rogue regulatory T cells
• Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
• Effects of immune‐related adverse events (<scp>irAEs</scp>) and their treatment on antitumor immune responses
• Immune checkpoint inhibitor–induced myocarditis is dependent on CD8 T cell–derived TNF and TNFR2 signaling
• Gut Microbiota–Related Biomarkers in Immuno-Oncology
• A Field Guide to Deploying AI Agents in Clinical Practice
• Immune checkpoint inhibitors and acute kidney injury
• Interplay between inflammasomes and PD-1/PD-L1 and their implications in cancer immunotherapy
• Single-cell RNA sequencing of baseline PBMCs predicts ICI efficacy and irAE severity in patients with NSCLC
• Microbiota-centered interventions to boost immune checkpoint blockade therapies
• A novel dataset for nuclei and tissue segmentation in melanoma with baseline nuclei segmentation and tissue segmentation benchmarks
• Aberrant RBMX expression is relevant for cancer prognosis and immunotherapy response
• Nano Delivery Strategy Opens Effective Avenues for the Treatment of Colorectal Cancer
• Self-adjuvanting α-helical polypeptide simultaneously delivers neoantigen mRNAs and activates dendritic cells to eradicate tumors
• Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review
• Incidence risk of PD-1/PD-L1–related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials
• Immune checkpoint Inhibitor–Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis
• Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers
• Orai1- and STIM1-mediated calcium signaling controls PD-L1 expression and modulates antitumor immunity in oral cancer

Related

• Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy
• A review of cancer immunotherapy toxicity
• First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitors
• Immune checkpoint inhibitor-related neurotoxicity: Incidence and management. A systematic review and meta-analysis
• Effects of immune‐related adverse events (<scp>irAEs</scp>) and their treatment on antitumor immune responses